Stockwinners Market Radar for August 30, 2019 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

18:15 EDT California American Water signs pact to purchase Bass Lake Water company - California American Water has entered into an agreement to acquire Bass Lake Water company's potable water distribution system, which serves approximately 1,000 customer connections in the Bass Lake community. Bass Lake is located approximately nine miles from Oakhurst, California, where California American Water is in the process of acquiring the Hillview Water Company. Hillview serves approximately 1,500 customer connections in the Madera County communities of Oakhurst, Coarsegold, and Raymond.

18:05 EDT Raytheon awarded $246.5M Navy contract action - Raytheon has been awarded $246.5M for an undefinitized contract action, performance-based logistics requirements contract for repair, upgrade, or replacement, required availability, required reliability, configuration management, inventory management and obsolescence management in support of the close-in weapon system, land-based Phalanx weapon system, rolling airframe missile, or RAM, and SeaRAM. This contract includes a two-year base period with one three-year option, which if exercised, will bring the contract ceiling value to $466.4M. Work will be performed in Louisville, Kentucky, and work is expected to be completed by August 2021; if the option is exercised, work will be completed by August 2024. Annual working capital funds will be obligated as individual task orders are issued and funds will not expire at the end of the current fiscal year. One firm was solicited for this non-competitive requirement under authority 10 U.S. Code 2304 and Federal Acquisition Regulation 6.302-1, with one offer received. Naval Supply Systems Command is the contracting activity..

18:03 EDT Celanese to increase prices on Amcel and Celcon by 5c per kg - Celanese announces price increases on its Amcel and Celcon polyacetal grades by 5c per kg, and other functionalized grades. The price increases will be effective September 1, 2019, or as contracts otherwise allow.

17:57 EDT Raytheon awarded $129.81M Army contract modification to procure missiles - Raytheon was awarded a $129.81M modification to a foreign military sales contract to procure missiles. Bids were solicited via the internet with one received. Work will be performed in Tucson, Arizona, with an estimated completion date of September 1, 2021. FY10 procurement of weapons and tracked combat vehicles, Army funds in the amount of $129.81M were obligated at the time of the award. U.S. Army Contracting Command is the contracting activity.

17:36 EDT Twitter says Dorsey's account now secure - Twitter's Communications account said that CEO Jack Dorsey's account, which had been "compromised" earlier, is now secure. The company said there is "no indication" that Twitter's systems have been compromised. Reference Link

17:19 EDT OSI Systems CEO sells 16.5K shares of common stock - In a regulatory filing, OSI Systems disclosed that its CEO Deepak Chopra sold 16.5K shares of common stock on August 29th. The total transaction size was $1.74M.

17:11 EDT Frank's International director Mosing sells 1.12M shares of common stock - In a regulatory filing, Frank's International disclosed that its director Steven Mosing sold 1.12M shares of common stock on August 29th-30th. The total transaction size was $2.43M.

16:33 EDT Brookfield announces delisting of its shares from Euronext Amsterdam - Brookfield Asset Management announced that it has requested the delisting of all Class A Limited Voting Shares from Euronext Amsterdam due to the very low trading volume, costs and administrative requirements related to its listing on Euronext Amsterdam. Brookfield shares will remain listed on the New York Stock Exchange and Toronto Stock Exchange. This request has received approval from the Board of Directors of Euronext Amsterdam N.V. The Brookfield shares are expected to be delisted from Euronext Amsterdam, effective Monday September 30, 2019 and the last trading date will be Friday September 27, 2019. The delisting procedure will allow Brookfield shareholders holding Brookfield shares listed on Euronext Amsterdam to sell their Brookfield Euronext Shares on the NYSE and/or TSX, Brookfield's primary listing exchanges.

16:21 EDT Scion Asset Management reports 5.1% stake in Tailored Brands - In a regulatory filing, Scion Asset Management disclosed a 5.1% stake in Tailored Brands, whcih represents 2.6M shares. The filing allows for activism.

16:20 EDT Gabelli reports 5.89% stake in Speedway Motorsports - In a regulatory filing, Gabelli disclosed a 5.89% stake in Speedway Motorsports, which represents about 2.4M shares. In the filing, Gabelli said that the firm does not intend to seek control of the company or participate in the management of the company.

16:17 EDT Lone Pine Capital reports 5% passive stake in Domino's Pizza - In a regulatory filing, Lone Pine Capital disclosed a 5% stake in Domino's Pizza, which represents over 2M shares. The filing does not allow for activism.

16:16 EDT Protalix receives listing deficiency letter from NYSE American - Protalix BioTherapeutics announced that it received a deficiency letter from NYSE American LLC stating that the company is not in compliance with the continued listing standards as set forth in Section 1003ai - iii of the NYSE American Company Guide as it has reported a stockholders' equity deficiency as of June 30, 2019 and net losses in its five most recent fiscal years ended December 31, 2018. The letter has no immediate effect on the listing of the company's common stock on the NYSE American. The company's common stock will trade on the NYSE American while it regains compliance with the continued listing standards.

16:14 EDT Air Lease EVP Korde sells 10.1K shares of common stock - In a regulatory filing, Air Lease disclosed that its EVP of Marketing Kishore Korde sold 10.1K shares of common stock on August 30th. The total transaction size was $419.5K.

15:55 EDT Twitter CEO Jack Dorsey's verified account seems to be hacked - The verified Twitter account of its CEO Jack Dorsey seems to be hacked as a host of offensive tweets are being posted.

15:33 EDT Xbox Live users experiencing sign in issues - Microsoft's Xbox Support Twitter account said that it is aware that some users are unable to sign in to Xbox Live, the company's online gaming service, and that its teams are "looking into it now." "We'll update when we have more info to share," the company tweeted. "Thanks for all the reports!" The news comes a day after Xbox Live players in South East Asia experienced issued connecting to the service's online store.

14:32 EDT Volkswagen announces $96.5M settlement over U.S. fuel economy ratings - Volkswagen Group of America, Inc. (VWGoA) announced that it has reached an agreement with private plaintiffs to resolve outstanding claims concerning the fuel economy ratings of certain Volkswagen Group Model Year 2013-2017 gasoline vehicles sold or leased in the United States. The fuel economy information for approximately 98,000 affected gasoline vehicles, or approximately 3.5% of Model Year 2013-2017 gasoline vehicles sold or leased in the United States, will be restated to reflect a discrepancy of one mile per gallon, when rounded according to the U.S.-specific "Monroney" label requirements. Under the proposed settlement, Volkswagen Group of America has agreed, among other terms, to reimburse eligible customers for the fuel economy restatement. Eligible customers will receive payments ranging from $5.40 to $24.30 for each month the vehicle is owned or leased. The total value of the settlement, which is subject to court approval, is approximately $96.5M. Volkswagen will also adjust its greenhouse gas credits to account for any excess credits associated with the fuel economy discrepancy. The adjustment is subject to final approval from the U.S. Environmental Protection Agency. "The settlement removes the uncertainty of protracted litigation and does not include any admission of liability or wrongdoing by Volkswagen," it added.

14:07 EDT Bloomin' Brands jumps 4% to $17.50 after Jana Partners reports stake

14:05 EDT Google contractors in Pittsburgh file for union election - The Pittsburgh Association of Tech Professionals said in a letter released August 29 that it has filed petition with the National Labor Relations Board for a union representation election with HCL, a tech contractor at Google's Bakery Square offices in Pittsburgh, Pennsylvania. HCL's 90 employees work side-by-side with those of the giant corporation for far less compensation and few, if any, of the perks. The PATP is a project sponsored by United Steelworkers union to help Pittsburgh and Southwestern Pennsylvania workers in high-tech fields organize and bargain collectively with their employers for improved working conditions and standards of living, the association said. With more than 66 percent of eligible employees signing cards seeking union representation, PATP members decided to file for the election so that they can "begin the process of bargaining for fair wages and benefits as quickly as possible." Reference Link

13:50 EDT FTE Networks Inc trading resumes

13:43 EDT FTE Networks says two investors levied against the company's bank account - FTE Networks disclosed that on August 9, Eagle Equities levied against the company's bank account in the amount of $529,287.56 and attempted to levy against a bank account of the company's subsidiary, Benchmark Builders, which attempted levy has since been withdrawn. On August 23, Eagle filed a verified petition for turnover against the company in the Supreme Court of the State of New York, County of New York, in which Eagle is seeking, among other remedies, an order directing the company to turn over to Eagle all of the assets of the company to satisfy the judgement of Eagle against the company and for the appointment of a receiver to administer and collect Eagle's interest in the company's assets. FTE's response in such proceeding is due on September 5. FTE added that another investor, which had obtained a judgment by confession in the amount of $306,043.57 on its note, levied against the company's bank account and attempted to levy against a benchmark bank account, which attempt has been withdrawn. The company believes "all of the outstanding Notes are void ab initio as the Company believes they were entered into fraudulently by the Company's prior management and without the knowledge or necessary authorization of the Company's board of directors." As a result, the company intends to dispute the judgements and the claims of such holders and to "vigorously defend" the litigations commenced by such investors. In addition, FTE Networks believes that holders of the notes have violated the NY Lien Law and have also engaged in other activities that are prohibited by the terms of the notes themselves. It added, "That conduct has injured the Company's business and reputation and has adversely affected the Company's common stock, causing significant financial loss to the Company's stockholders. The Company intends to hold such holders liable for the full amount of such damages."

13:16 EDT Nektar says FDA missed NKTR-181 action date of August 29 - Nektar Therapeutics disclosed earlier this morning that as of this morning, the company has not received an action letter from the FDA regarding its new drug application for NKTR-181, thereby resulting in the FDA not meeting the PDUFA goal date of August 29. Nektar said it "will continue to work closely with the FDA as they continue their review of the NDA for NKTR-181." The company on July 23 announced that the FDA is postponing its product-specific advisory committee meetings for opioid analgesics, including the one previously scheduled for August 21, to discuss the new drug application for the NKTR-181 product, while the agency continues to consider a number of scientific and policy issues relating to this class of drugs. The letter stated that the FDA's reason for postponing the advisory committee meeting for NKTR-181 is not unique to the NKTR-181 product, the company added. Shares of Nektar are down 1c to $17.35 in afternoon trading.

13:06 EDT Baker Hughes reports U.S. rig count down 12 to 904 rigs - Baker Hughes reports that the U.S. rig count is down 12 rigs from last week to 904, with oil rigs down 12 to 742, gas rigs unchanged at 162, and miscellaneous rigs unchanged at zero. The U.S. Rig Count is down 144 rigs from last year's count of 1,048, with oil rigs down 120, gas rigs down 22, and miscellaneous rigs down two to zero. The U.S. Offshore Rig Count is unchanged at 28 and up 10 rigs year-over-year. The Canada Rig Count is up 11 rigs from last week to 150, with oil rigs up 10 to 105 and gas rigs up one to 45. The Canada Rig Count is down 78 rigs from last year's count of 228, with oil rigs down 46 and gas rigs down 32.

12:09 EDT United extends 737 Max cancellations to December from November - United Airlines (UAL) extended cancellations of Boeing's (BA) 737 Max to December 19 from November 3. The airline expects 2,100 flight cancellations for September, 2,900 for October, 2,800 for November, and 1,700 for December.

12:00 EDT Antero Resources falls -9.3% - Antero Resources is down -9.3%, or -32c to $3.06.

12:00 EDT Yext falls -13.0% - Yext is down -13.0%, or -$2.38 to $15.96.

12:00 EDT Borr Drilling rises 10.4% - Borr Drilling is up 10.4%, or 53c to $5.65.

11:58 EDT Vical shareholders approve merger, 1-for-7 reverse stock split - Vical Incorporated (VICL) announced that its stockholders voted to approve the proposals required to complete the merger transaction with Brickell Biotech. As previously disclosed, Vical entered into an agreement and plan of merger and reorganization with Brickell and Victory Subsidiary, and each of Vical's and Brickell's board of directors unanimously approved the merger in June. The board of directors of Vical has also determined that the reverse stock split of the company's common stock will be effected at a ratio of 1-for-7 and is expected to be completed immediately prior to the consummation of the merger. The merger is expected to close on Saturday, August 31. Vical expects to change its name from "Vical Incorporated" to "Brickell Biotech" with its common stock expected to begin trading on the Nasdaq Capital Market under the stock symbol "BBI" on Tuesday, September 3.

10:00 EDT Alexion falls 8% after patent board opens review of Soliris patents - Shares of Alexion Pharmaceuticals (ALXN) are lower after the Patent Trial and Appeal Board of the United States Patent and Trademark Office said it would review three of the company's patents for its blood disorder drug Soliris following a challenge by Amgen (AMGN). Amgen is contesting the issuance of new Soliris patents that would extend the drug's market exclusivity to 2027, Reuters pointed out. The inter-party review on the patents will take about a year, the Patent Trial and Appeal Board noted, according to Bloomberg. Shares of Alexion are down 8%, or $8.82, to $103.35 in early trading. Amgen is up 76c to $207.74. Reference Link

10:00 EDT Cooper Companies falls -8.3% - Cooper Companies is down -8.3%, or -$27.39 to $301.20.

10:00 EDT Contura Energy rises 10.9% - Contura Energy is up 10.9%, or $2.93 to $29.86.

10:00 EDT MSG Networks rises 12.8% - MSG Networks is up 12.8%, or $1.84 to $16.16.

09:47 EDT Cooper Companies falls -8.1% - Cooper Companies is down -8.1%, or -$26.49 to $302.10.

09:47 EDT Big Lots rises 15.8% - Big Lots is up 15.8%, or $3.47 to $25.48.

09:47 EDT IHS Markit rises 658600.0% - IHS Markit is up 658600.0%, or $65.86 to $65.87.

09:18 EDT 1st Constitution Bancorp receives FDIC approval for Shore Community Bank merger - 1ST Constitution Bancorp (FCCY) announced that it has received approval from the Federal Deposit Insurance Corporation of the proposed merger of Shore Community Bank (SHRC) with and into 1ST Constitution Bank. The merger is subject to a number of conditions, including the approval by the Shore shareholders at a special meeting of shareholders scheduled to be held on October 18, 2019. The closing of the transaction is anticipated to take place during the fourth quarter of 2019.

09:09 EDT Campbell sees first half results negatively impacted by marketing investmentment - Campbell Soup's outgoing CFO Anthony DiSilvestro said the company expects first half results negatively impacted by accelerated marketing investment to support the company's snacks business and to improve the performance of U.S. soup.

09:04 EDT CNH CEO calls for USMCA passage to back U.S. farmers and manufacturers - The CEO of CNH Industrial, Hubertus Muhlhauser, urged prompt Congressional passing of the United States-Mexico-Canada Agreement, USMCA, and highlighted challenges U.S. farmers currently face due to global trade tensions in a meeting with two congressmen at the company's North American headquarters on August 29. Canada and Mexico represent the top export markets for many U.S. manufactured products, making a strong and stable North American trade relationship a priority. "Trade tensions and tariffs are impacting America's farmers, causing increasing uncertainty for rural families, businesses and communities," said Mr. Muhlhauser. "That's why quick ratification by the U.S. Congress of the United States-Mexico-Canada Agreement is essential, and we welcomed this opportunity to share the need for swift action on trade issues with congressional representatives." Congressman Bill Foster, who represents Burr Ridge as part of Illinois' 11th District and Congressman Sean Casten, from the neighboring 6th District, were part of the roundtable discussion. "Illinois is a leader in agriculture because of its hardworking farm families and world-leading technology from suppliers like CNH Industrial in Burr Ridge. Farming provides American jobs and feeds the nation and the world. I am committed to supporting farmers in Illinois and across the country and am proud to represent the workers, employees and researchers of CNH Industrial," said Rep. Foster.

09:02 EDT Arthur J. Gallagher acquires University Services business of Garnett-Powers - Arthur J. Gallagher & Co. announced the acquisition of the University Services business of Mission Viejo, California-based benefits broker and consultant Garnett-Powers & Associates Insurance Services. Terms of the transaction were not disclosed. Established in 1996, Garnett-Powers & Associates' University Services business offers medical, dental, vision, life, AD&D and disability insurance plans to university postdoctoral scholars and visiting scholars.

08:46 EDT Blue Capital declares special distribution of $1.51 per common share - Blue Capital Reinsurance Holdings has declared a special distribution of $1.51 per common share, which is payable on September 30, 2019 to holders of record as of September 16, 2019.

08:44 EDT Xynomic reports interim data from Phase 1b study of abexinostat w/ Keytruda - Xynomic Pharmaceuticals Holdings announced encouraging interim data from an ongoing Phase 1b study of its lead candidate abexinostat, an orally dosed, hydroxamic acid-based small molecule histone deacetylase inhibitor , in combination with Keytruda, for the treatment of multiple solid tumors. The trial is being conducted at University of California, San Francisco. The interim data will also be presented at the 3rd World-China Immunotherapy & Gene Therapy Congress 2019. This Phase 1b trial explores abexinostat in combination with pembrolizumab to treat patients with prior progression on Keytruda or other immune checkpoint inhibitor treatments. A total of 7 patients with prior progression on anti-PD1/PD-L1 treatment were enrolled in the Dose Escalation portion of the study. Tumor types included melanoma, urothelial carcinoma, neuroendocrine carcinoma, and esophageal squamous cell carcinoma. The median number of lines of prior systemic therapy was 3. Median age of patient population was 61. In the two dose levels tested, there were no dose-limiting toxicities. The maximally tolerated dose was not reached, and the recommended Phase 2 dose is abexinostat 45 mg/m2 BID on days 1-4, 8-11 of a 21 day cycle in conjunction with pembrolizumab 200 mg IV on day 1. There were no treatment-related grade greater than or equal to 3 or serious adverse events. The most common Grade 1-2 adverse events were diarrhea, rash, thrombocytopenia, and dysgeusia. 2 out of 7 patients experienced stable disease for greater than 6 months. 1 of these 2 patients has pembrolizumab-refractory urothelial carcinoma and remains on treatment for 6+ months with ongoing 20% reduction in tumor size from baseline. Enrollment in Dose Expansion portion of this trial is ongoing to ascertain the response rate and disease control rate across tumor types. The trial is targeting to enroll a total of approximately 42 patients in the U.S.

08:21 EDT Hexindai CFO Johnson Qisen Zhang to leave company, Kerrie Rui Zhang to succeed - Hexindai announced that Johnson Qisen Zhang, Hexindai's CFO, will depart the company on August 30. Zhang's resignation was not the result of any disagreements with the company on any matters relating to its operations, policies or practices. Hexindai named Kerrie Rui Zhang as the new CFO, effective upon Zhang's departure. Zhang currently serves as Hexindai's Financial Reporting Director, and brings more than 12 years of accounting and financial related experience to the role, including over two years at Hexindai.

08:18 EDT Principia Biopharma appoints Shawn Tomasello to board of directors - Principia Biopharma (PRNB) announced the appointment of Shawn Tomasello to its Board of Directors. From 2015 to 2018, Tomasello was chief commercial officer at leading immuno-oncology cell therapy company Kite Pharma, which was acquired by Gilead Sciences (GILD).

08:15 EDT Bionano Genomics presents preliminary Saphyr data at CGC annual meeting - Bionano Genomics announced the release on its website of video presentations of results from two key studies presented this month at the 2019 Cancer Genomics Consortium Annual Meeting. The presentations include: A preliminary read-out by Professor Brynn Levy, Director of Cytogenetics at Columbia University, regarding 11 patient samples analyzed and unblinded from a multi-center clinical validation study. This study compares Saphyr to technologies used in traditional cytogenetics workflows for patient testing in oncology and is being run by a consortium of leading cytogenetics teams at institutions in the United States, including Columbia University, MD Anderson Cancer Center, Mayo Clinic, University of Washington, Penn State University, Augusta University and PathGroup. In each of the 11 samples, Saphyr detected all known clinical variants identified by various combinations of karyotype, Fluorescent In-Situ Hybridization , and Chromosomal MicroArray, which define the current standard of care in cytogenetics. Some of the variants identified include: in Acute Myeloid Leukemia samples, a large inversion on chromosome 16, which creates a CBFB MYH11 fusion; in one B-Cell Acute Lymphoblastic Leukemia sample, a BCR-ABL1 translocation, and deletions of tumor suppressor genes IKZF1 and CDK6; and in a separate B-ALL sample, a NF1 deletion, which is a well-known risk factor for childhood leukemia. This detailed characterization of variants potentially helps to enable a precise treatment tailored to the specific patient's tumor. During his presentation, Dr. Levy discussed the strong concordance of the size of the deletions and the breakpoints identified by Saphyr with those determined by microarray results. Based on the preliminary results, Dr. Levy concluded that Saphyr has the potential to be a powerful new tool in cytogenomics for assessing chromosome structure and copy number. Upon completion of the clinical validation phase, Dr. Levy's team plans to evaluate the benefits of using the Saphyr system for discovery of novel variants by analyzing samples previously deemed "normal" by karyotype, FISH, and CMA to identify the existence of any recurring abnormalities with prognostic and therapeutic value that may have been missed by traditional methods. A preliminary summary by Rashmi Kanagal-Shamanna, Microarray Director in the Molecular Diagnostics Lab of MD Anderson Cancer Center, of a study regarding results from the analysis of 7 patient samples with Myelodysplastic Syndrome, a precursor to leukemia. In addition to identifying all clinically relevant variants previously detected by karyotyping and CMA, Saphyr revealed additional structural variants of research interest that were missed by these methods, including deletions of the TP53 and TET2 genes, which potentially have prognostic and therapeutic implications. Use of the Saphyr system further enabled elucidation of a complex rearrangement involving three chromosomes, with deletions and duplications at the breakpoints, all of which were not captured by other cytogenetic methods. Additionally, Saphyr facilitated precise mapping of variants within genomic coordinates, especially in cases involving complex rearrangements. Dr. Kanagal-Shamanna stated that the high concordance between results of Saphyr and conventional techniques provides proof-of-concept for potential use of Saphyr as a single-platform for comprehensive assessment of all structural variants, including copy number variants and balanced rearrangements. In hematological malignancies, this eliminates the need for cell culture and provides higher resolution than standard of care assays.

08:10 EDT Paratek Pharmaceuticals jumps 9% after Nuzyra study meets endpoints - Shares of Paratek Pharmaceuticals are up 9.14% or 31c to $3.70 per share in pre-market trading on Friday after reporting that its Nuzyra study met endpoints.

08:09 EDT Novelion Therapeutics provides update on delisting, Aegerion bankruptcy case - Novelion Therapeutics announced that, further to its press release dated August 21, 2019, it has received a notice from the Nasdaq Hearings Panel granting a 15-calendar day stay, until September 12, 2019, of the delisting of the Company's common stock from The Nasdaq Stock Market in response to the Company's request for a hearing. Upon expiration of the stay period, the Company's common stock will be suspended from trading unless the Panel extends the stay of delisting pending the hearing. The hearing is currently scheduled for October 3, 2019. On May 20, 2019, as previously disclosed Aegerion Pharmaceuticals, Inc. and Aegerion Pharmaceuticals Holdings, each a subsidiary of the Company, filed voluntary petitions under chapter 11 of Title 11 of the United States Code in the United States Bankruptcy Court for the Southern District of New York and Aegerion entered into a Plan Funding Agreement with Amryt Pharma setting forth the terms and conditions of the acquisition by the Plan Investor of 100% of the outstanding equity interests of the reorganized Aegerion Pharmaceuticals, Inc. On August 22, 2019, each of the three classes of creditors entitled to vote on Aegerion's chapter 11 plan voted to accept the plan. There is a hearing scheduled for September 5, 2019 at which Aegerion will seek an order of the Bankruptcy Court confirming the chapter 11 plan and authorizing Aegerion to close on the transactions contemplated thereunder. Further, on August 22, 2019, the "go-shop" period established pursuant to the terms of the Plan Funding Agreement expired. During the "go shop" period, Aegerion did not receive any superior alternative transaction proposals. As previously reported, as a result of the Aegerion bankruptcy proceedings, the Company analyzed and evaluated the appropriate accounti treatment of its investment in Aegerion and concluded that Aegerion's financials should be deconsolidated from the Company's financial statements (the "Deconsolidation"), commencing with the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2019. The Company is diligently proceeding with its accounting efforts to effect the Deconsolidation and intends to file its Form 10-Q and related filings as soon as that work has been completed, which the Company currently expects will be in the fourth quarter of 2019.

08:05 EDT Paratek says the Lancet published results of Nuzrya trial tat met endpoints - Paratek Pharmaceuticals announced The Lancet Infectious Diseases published detailed results from the OASIS-2 Phase 3 clinical trial of NUZYRA . Once-daily, oral NUZYRA met all primary and secondary clinical study endpoints and was shown to be safe and effective for the treatment of acute bacterial skin and skin structure--"The incidence of skin infections that require hospitalization has substantially increased due, in part, to the emergence of community-acquired MRSA. These infections are estimated to cause almost 900,000 hospital admissions and 3.4 million emergency department visits each year and place a significant financial burden on the healthcare system," said Keith Kaye, MD.

07:40 EDT Campbell Soup up 5.1% after reporting Q4 results, giving FY20 guidance

07:32 EDT LCI Industries subsidiary acquires Ciesse - LCI Industries announced that its subsidiary, LCI Italy, or LCI, has acquired Ciesse, a supplier of railway interior products and systems, headquartered in Rignano sull'Arno, Italy, effective August 31. Ciesse had trailing twelve-month sales of approximately EUR22.5M through June.

07:04 EDT DMC Global discontinuing production at Siberia plant - DMC Global announced its DynaEnergetics oilfield products business has completed a series of capacity expansion initiatives at its plants in North America and Germany. The new capacity has significantly improved DynaEnergetics' operating efficiencies and enabled the business to more effectively serve its global customer base. Capitalizing on its more efficient manufacturing footprint, DynaEnergetics is discontinuing production at its plant in Tyumen, Siberia. DMC expects to record $15M to $20M in non-cash charges associated with the closure during the second half of 2019. Approximately half of the charges relate to foreign currency translation losses incurred since the Tyumen plant commenced operations in 2011. Management expects an additional $2M to $2.5M in cash wind-down and severance expense, as the closure will reduce DynaEnergetics' workforce by 47 people. DMC's management said it is maintaining its prior 2019 financial guidance, including for sales and adjusted earnings per diluted share. Moreover, the consolidation of manufacturing capacity is expected to further strengthen DMC's operating performance and returns on invested capital.

06:56 EDT Tyson Foods partners with Grupo Vibra - Tyson Foods has reached an agreement to invest in the foods division of Grupo Vibra, a Brazilian producer and exporter of poultry products. Once completed, the deal will give Tyson Foods more flexibility in serving customers in key global markets. Terms of the agreement were not disclosed, and the transaction is still subject to approval by Brazilian regulators. As part of the agreement, Grupo Vibra will spin-off its genetics multiplication business, Agrogen, into a separate company.

06:35 EDT NGL Energy Partners announces $150M unit repurchase program - NGL Energy Partners announced that the Board of Directors of its general partner has authorized a unit repurchase program, under which NGL may repurchase up to $150M of its outstanding units representing limited partnership interests of NGL through September 30, 2021. The unit repurchase program authorization does not obligate NGL to repurchase any dollar amount or number of its units and repurchases may be commenced or suspended from time to time without prior notice.

06:28 EDT AirAsia signs deal with Airbus for 12 A330neo, 30 A321XLR aircraft - AirAsia signed two major agreements with Airbus, covering the order of an additional 12 A330neo and 30 A321XLR aircraft, as well as a memorandum of agreement to support the development of the Malaysian aerospace industry. As part of the deal, Airbus will expand its maintenance, repair and overhaul presence in Malaysia and establish the Airbus Malaysia Digital Initiative to enhance the competitiveness of the local aerospace sector through the application of new digital technologies, in line with the government's vision to make Malaysia a regional aerospace hub. Airbus will also boost its commitment to the Aerospace Malaysia Innovation Centre - of which it is a founding member - by appointing an Innovation Technical Director and increasing its funding for joint research programmes, including into the production of sustainable aviation biofuels in Malaysia. AirAsia also signed an agreement for a firm order of 12 additional Airbus A330neo aircraft, and 30 state-of-the-art A321XLR aircraft, to join AirAsia's future long-haul fleet.

06:19 EDT JinkoSolar sees Q3 shipments 3.2 GW-3.5 GW

06:06 EDT Univar selected as exclusive U.S. distributor by BASF for Lupragen - Univar (UNVR) has been selected as BASF's (BASFY) exclusive authorized distributor for Lupragen amine catalysts throughout the United States. BASF has more than 15 polyurethane, or PUR, amine catalysts in its product portfolio. The company markets reaction accelerators under the Lupragen brand, including low-emission PUR catalysts. Such catalysts are usually tertiary amines. They are required to facilitate the reaction of the main components' isocyanate and polyol. Depending on the catalyst choice, the polyurethane forming process can be controlled to favor the gelling or blowing reaction. This behavior leads to PUR material with the desired properties, depending on whether the final product is to be a rigid, semi-rigid or flexible foam.

05:07 EDT AT&T, CWA reach tentative agreements in Southeast contract talks - AT&T announced that it has reached three tentative agreements with Communications Workers of America District 3 in Southeast CWA contract negotiations. The three agreements include the Southeast wireline agreement, BellSouth Telecommunications - Utility Operations and AT&T Billing Southeast. The five-year agreements collectively cover about 20,000 employees in CWA District 3, which includes Alabama, Florida, Georgia, Kentucky, Louisiana, Mississippi, North Carolina, South Carolina, and Tennessee. The agreements will be submitted to the union's membership for ratification votes in coming days.